# Julia L Glade Bender

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 81 papers | 3,605 citations | 147566 31 h-index | 138251 58 g-index |
| 83 all docs | 83 docs citations | 83 times ranked | 5319 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Psychosocial Needs and Preferences for Care among Adolescent and Young Adult Cancer Patients (Ages 15â€“39): A Qualitative Study. Cancers, 2022, 14, 710. | 1.7 | 14 |
| 2 | CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma. Cancer Research, 2022, 82, 1110-1127. | 0.4 | 3 |
| 3 | Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers. Nature Communications, 2022, 13, 2485. | 5.8 | 31 |
| 4 | Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications, 2022, 13, . | 5.8 | 63 |
| 5 | Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nature Medicine, 2022, 28, 1581-1589. | 15.2 | 16 |
| 6 | Opportunities and Challenges in Drug Development for Pediatric Cancers. Cancer Discovery, 2021, 11, 545-559. | 7.7 | 25 |
| 7 | Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nature Cancer, 2021, 2, 357-365. | 5.7 | 74 |
| 8 | Stepwise Strategic Mitigation Planning in a Pediatric Oncology Center During the COVID-19 Pandemic. Journal of Pediatric Oncology Nursing, 2021, 38, 176-184. | 1.5 | 2 |
| 9 | Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. Archives of Pathology and Laboratory Medicine, 2021, 145, 1564-1568. | 1.2 | 4 |
| 10 | Bromodomain and extra-terminalÂinhibitorsâ€"A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in childrenâ€"ACCELERATE. European Journal of Cancer, 2021, 146, 115-124. | 1.3 | 10 |
| 11 | Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. Journal of Clinical Oncology, 2021, 39, 3822-3828. | 0.8 | 4 |
| 12 | Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precision Oncology, 2021, 5, 1840-1852. | 1.5 | 8 |
| 13 | Unrealistic parental expectations for cure in poorâ€prognosis childhood cancer. Cancer, 2020, 126, 416-424. | 2.0 | 34 |
| 14 | Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1â€“2 trial. Lancet Oncology, The, 2020, 21, 121-133. | 5.1 | 204 |
| 15 | A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas. Journal of Neuro-Oncology, 2020, 149, 437-445. | 1.4 | 5 |
| 16 | Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Clinical Cancer Research, 2020, 26, 2297-2307. | 3.2 | 28 |
| 17 | A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies. Pediatric Hematology and Oncology, 2020, 37, 465-474. | 0.3 | 12 |
| 18 | Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. Journal of Pain and Symptom Management, 2020, 60, 782-789. | 0.6 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | COVIDâ€19 disease in New York City pediatric hematology and oncology patients. Pediatric Blood and Cancer, 2020, 67, e28420. | 0.8 | 44 |
| 20 | Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2020, 38, 2160-2169. | 0.8 | 98 |
| 21 | Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations. JCO Precision Oncology, 2020, 4, 341-347. | 1.5 | 29 |
| 22 | Characterization of on-target adverse events caused by TRK inhibitor therapy. Annals of Oncology, 2020, 31, 1207-1215. | 0.6 | 39 |
| 23 | Abstract 1122: Germline mutation prevalence in young adults with cancer. , 2020, , . | | 3 |
| 24 | Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorhamâ€“Stout disease. Pediatric Blood and Cancer, 2019, 66, e27614. | 0.8 | 81 |
| 25 | Nutritional status and clinical outcomes in pediatric patients with solid tumors : A systematic review of the literature. Seminars in Oncology, 2019, 46, 48-56. | 0.8 | 52 |
| 26 | Identification of a secondary RET mutation in a pediatric patient with relapsed acute myeloid leukemia leads to the diagnosis and treatment of asymptomatic metastatic medullary thyroid cancer in a parent: a case for sequencing the germline. Journal of Physical Education and Sports Management, 2019, 5, a003889. | 0.5 | 2 |
| 27 | Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Childrenâ€™s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. F1000Research, 2019, 8, 493. | 0.8 | 57 |
| 28 | Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors. Frontiers in Oncology, 2019, 9, 108. | 1.3 | 49 |
| 29 | Duality of Purpose: Participant and Parent Understanding of the Purpose of Genomic Tumor Profiling Research Among Children and Young Adults With Solid Tumors. JCO Precision Oncology, 2019, 3, 1-17. | 1.5 | 11 |
| 30 | Integrated analysis of longâ€term growth and bone development in pediatric and adolescent patients receiving bevacizumab. Pediatric Blood and Cancer, 2019, 66, e27487. | 0.8 | 5 |
| 31 | Abstract 3104: A high prevalence of chromosomal translocations as drivers in high-risk pediatric solid cancers. , 2019, , . | | 0 |
| 32 | Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatric Blood and Cancer, 2018, 65, e27023. | 0.8 | 31 |
| 33 | INI1 negative hepatoblastoma, a vanishing entity representing malignant rhabdoid tumor. Human Pathology: Case Reports, 2018, 12, 42-47. | 0.2 | 2 |
| 34 | Recurrent EML4â€“NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Modern Pathology, 2018, 31, 463-473. | 2.9 | 117 |
| 35 | Whole-Genome and Whole-Exome Sequencing in Pediatric Oncology: An Assessment of Parent and Young Adult Patient Knowledge, Attitudes, and Expectations. JCO Precision Oncology, 2018, 2, 1-11. | 1.5 | 5 |
| 36 | Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. European Journal of Cancer, 2018, 100, 27-34. | 1.3 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Pediatric oncology enters an era of precision medicine. Current Problems in Cancer, 2017, 41, 194-200. | 1.0 | 39 |
| 38 | Irinotecanâ€“temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2017, 18, 946-957. | 5.1 | 205 |
| 39 | Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse. Journal of Pediatric Hematology/Oncology, 2017, 39, 560-564. | 0.3 | 8 |
| 40 | Emerging and investigational therapies for neuroblastoma. Expert Opinion on Orphan Drugs, 2017, 5, 355-368. | 0.5 | 27 |
| 41 | A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma. Journal of Physical Education and Sports Management, 2017, 3, a001396. | 0.5 | 25 |
| 42 | Clinical trial enrollment of adolescents and young adults with sarcoma. Cancer, 2017, 123, 3434-3440. | 2.0 | 29 |
| 43 | Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer. Supportive Care in Cancer, 2017, 25, 701-708. | 1.0 | 37 |
| 44 | Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience. Frontiers in Pediatrics, 2017, 5, 265. | 0.9 | 29 |
| 45 | Treatment of Metastatic, Refractory Alveolar Soft Part Sarcoma: Case Reports and Literature Review of Treatment Options in the Era of Targeted Therapy. Journal of Pediatric Hematology/Oncology, 2016, 38, e169-e172. | 0.3 | 11 |
| 46 | Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Medicine, 2016, 8, 133. | 3.6 | 147 |
| 47 | Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. Pediatric Blood and Cancer, 2016, 63, 1974-1982. | 0.8 | 49 |
| 48 | A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Medicine, 2016, 8, 116. | 3.6 | 15 |
| 49 | Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors. JAMA Oncology, 2016, 2, 608. | 3.4 | 172 |
| 50 | Molecular Profiling of High-Risk Pediatric Acute Myeloid Leukemia. Blood, 2016, 128, 5250-5250. | 0.6 | 1 |
| 51 | Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. Journal of Physical Education and Sports Management, 2015, 1, a000471. | 0.5 | 39 |
| 52 | Growth plate abnormalities in pediatric cancer patients undergoing phase 1 antiâ€angiogenic therapy: A report from the children's oncology group phase I consortium. Pediatric Blood and Cancer, 2015, 62, 45-51. | 0.8 | 27 |
| 53 | Overcoming challenges to meaningful informed consent for whole genome sequencing in pediatric cancer research. Pediatric Blood and Cancer, 2015, 62, 1374-1380. | 0.8 | 27 |
| 54 | Translating genomic discoveries to the clinic in pediatric oncology. Current Opinion in Pediatrics, 2015, 27, 34-43. | 1.0 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Clinical Implementation of Genomic Sequencing in Pediatric Oncology: Identification and Valuation of Resources and Costs Associated with Next-Generation Sequencing. Value in Health, 2014, 17, A645. | 0.1 | 0 |
| 56 | Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study. BMC Research Notes, 2014, 7, 256. | 0.6 | 9 |
| 57 | Knowledge, attitudes, and beliefs of parents toward whole-genome sequencing in pediatric cancer.. Journal of Clinical Oncology, 2014, 32, 10090-10090. | 0.8 | 0 |
| 58 | Pediatric allo-SCT for malignant and non-malignant diseases: impact on health-related quality of life outcomes. Bone Marrow Transplantation, 2013, 48, 787-793. | 1.3 | 20 |
| 59 | Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Journal of Clinical Oncology, 2013, 31, 3034-3043. | 0.8 | 138 |
| 60 | A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research, 2012, 18, 5081-5089. | 3.2 | 22 |
| 61 | A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research, 2012, 18, 6011-6022. | 3.2 | 103 |
| 62 | Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Childrenâ€™s Oncology Group study. Cancer Chemotherapy and Pharmacology, 2012, 69, 1021-1027. | 1.1 | 31 |
| 63 | Drug Induced Non-Specific Interstitial Pneumonitis. , 2011, , . | | 0 |
| 64 | Clinical Development of VEGF Signaling Pathway Inhibitors in Childhood Solid Tumors. Oncologist, 2011, 16, 1614-1625. | 1.9 | 23 |
| 65 | Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study. Clinical Cancer Research, 2011, 17, 5113-5122. | 3.2 | 104 |
| 66 | Angiogenesis and vascular targeting in Ewing sarcoma. Cancer, 2010, 116, 749-757. | 2.0 | 58 |
| 67 | Neuropsychological functioning of children treated with intensive chemotherapy followed by myeloablative consolidation chemotherapy and autologous hematopoietic cell rescue for newly diagnosed CNS tumors: An analysis of the Head Start II survivors. Pediatric Blood and Cancer, 2010, 54, 429-436. | 0.8 | 47 |
| 68 | Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatric Blood and Cancer, 2010, 55, 254-259. | 0.8 | 104 |
| 69 | Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatric Blood and Cancer, 2009, 52, 669-671. | 0.8 | 25 |
| 70 | Phase I study of sorafenib in children with refractory solid tumors: A Children's Oncology Group Phase I Consortium trial. Journal of Clinical Oncology, 2009, 27, 10012-10012. | 0.8 | 5 |
| 71 | Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study. Journal of Clinical Oncology, 2008, 26, 399-405. | 0.8 | 240 |
| 72 | Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.. Blood, 2008, 112, 1919-1919. | 0.6 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to γ-secretase inhibitors. Leukemia, 2006, 20, 1279-1287. | 3.3 | 141 |
| 74 | Inhibition of Cyclooxygenase-2 Disrupts Tumor Vascular Mural Cell Recruitment and Survival Signaling. Cancer Research, 2006, 66, 4378-4384. | 0.4 | 34 |
| 75 | Current Issues in Wilms Tumor Management. Current Problems in Cancer, 2005, 29, 223-260. | 1.0 | 38 |
| 76 | Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resistance Updates, 2004, 7, 289-300. | 6.5 | 82 |
| 77 | VEGF blocking therapy in the treatment of cancer. Expert Opinion on Biological Therapy, 2003, 3, 263-276. | 1.4 | 159 |
| 78 | Anti-HPA-3A induces severe neonatal alloimmune thrombocytopenia. Journal of Pediatrics, 2001, 138, 862-867. | 0.9 | 84 |
| 79 | Basic Principles of Gene Transfer in Hematopoietic Stem Cells. , 1999, 36, 1-19. | | 4 |
| 80 | VEGF blocking therapy in the treatment of cancer. , 0, . | | 1 |
| 81 | COVID-19 in New York City Pediatric Hematology and Oncology Patients. SSRN Electronic Journal, 0, , . | 0.4 | 1 |